In the WHO 2022 classification, a distinct diagnostic category termed “MDS with biallelic TP53 inactivation (MDS-biTP53)” has been introduced, defined by the presence of multiple TP53 alterations leading to complete loss of p53 function [2]. This evidence concerns the gene TP53 and myelodysplastic syndrome.